Integra LifeSciences (NASDAQ:IART) Stock Moved Up to “Buy” by Wall Street Zen

Wall Street Zen upgraded shares of Integra LifeSciences (NASDAQ:IART) from a hold rating to a buy rating in a research note released on Saturday morning,Wall Street Zen reports.

Several other analysts also recently commented on the company. Citizens Jmp reduced their target price on Integra LifeSciences from $25.00 to $22.00 and set a “market outperform” rating for the company in a research note on Thursday, October 22nd. Weiss Ratings raised Integra LifeSciences from a “sell (e+)” rating to a “sell (d+)” rating in a research note on Monday, October 26th. Wells Fargo & Company set a $13.00 price target on Integra LifeSciences and gave the stock an “equal weight” rating in a report on Thursday, October 22nd. Citigroup reissued an “outperform” rating on shares of Integra LifeSciences in a research note on Thursday, October 22nd. Finally, JPMorgan Chase & Co. reduced their price objective on Integra LifeSciences from $17.00 to $14.00 and set an “underweight” rating for the company in a research note on Thursday, October 22nd. Two investment analysts have rated the stock with a Buy rating, five have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average target price of $16.12.

Integra LifeSciences Trading Down 0.6%

Shares of IART stock opened at $12.75 on Friday. Integra LifeSciences has a fifty-two week low of $8.70 and a fifty-two week high of $20.49. The company has a debt-to-equity ratio of 1.67, a quick ratio of 2.11 and a current ratio of 3.62. The stock has a 50 day simple moving average of $14.83 and a two-hundred day simple moving average of $14.08. The company has a market cap of $991.95 million, a P/E ratio of 75.00, a PEG ratio of 0.50 and a beta of 1.21.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Wednesday, October 21st. The life sciences company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.03. The firm had revenue of $411.18 million for the quarter, compared to analysts’ expectations of $413.16 million. Integra LifeSciences had a return on equity of 18.63% and a net margin of 0.79%. During the same period in the prior year, the business earned ($0.07) EPS. Research analysts forecast that Integra LifeSciences will post 2.34 earnings per share for the current year.

Hedge Funds Weigh In On Integra LifeSciences

Large investors have recently bought and sold shares of the stock. Paradigm Capital Management Inc. NY purchased a new position in shares of Integra LifeSciences in the 2nd quarter worth about $61,766,000. Wellington Management Group LLP increased its holdings in Integra LifeSciences by 12.4% during the second quarter. Wellington Management Group LLP now owns 1,461,104 shares of the life sciences company’s stock worth $26,241,000 after buying an additional 160,814 shares during the last quarter. Bank of America Corp DE increased its holdings in Integra LifeSciences by 71.4% during the first quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company’s stock worth $13,325,000 after buying an additional 589,408 shares during the last quarter. Glenmede Trust Co. NA increased its holdings in Integra LifeSciences by 27.4% during the first quarter. Glenmede Trust Co. NA now owns 984,686 shares of the life sciences company’s stock worth $9,276,000 after buying an additional 211,774 shares during the last quarter. Finally, Access Investment Management LLC raised its position in Integra LifeSciences by 39.5% in the third quarter. Access Investment Management LLC now owns 564,982 shares of the life sciences company’s stock worth $9,198,000 after acquiring an additional 159,980 shares during the period. 84.78% of the stock is currently owned by institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, orthopedics and wound care. Its portfolio includes medical devices, surgical instruments and regenerative tissue technologies designed to help healthcare professionals treat complex conditions and support patient recovery.

Integra’s neurosurgical products include dural repair products, cerebrospinal fluid management systems, cranial stabilization devices and specialized surgical instruments.